Creative Biolabs is well equipped and versed in modulating tumor-associated macrophages (TAMs). One approach is to inhibit circulating monocyte recruitment into the tumor. Our professional technical scientists and abundant experience make us a perfect partner to help our clients' projects in this field.
Tumor promotion by macrophages in different cancer models and increased macrophage prevalence correlates with poor overall survival in many human cancers. This provides a strong basis for targeting macrophages independently at different levels and comparing responses to different targeting strategies. One strategy is to inhibit the recruitment or infiltration of monocytes into tumors. Strong evidence indicates that the accumulation of macrophages in tumors is due to the continuous recruitment of monocytes from the circulation in response to TDFs. These TDFs are key mediators in the crosstalk between monocytes and tumor cells. Several C-C chemokine ligands, such as CCL2, are produced by tumor cells and stroma and they are a major chemoattractant for monocytes, which can then develop into macrophages and promote invasiveness, metastasis and correlate with poor prognosis. CCL2 has been described as the major TDF involved in monocyte recruitment, through the CCL2-C-C chemokine receptor type 2 (CCR2) axis. Another TDF is colony-stimulating factor-1 (CSF-1). CSF1/colony-stimulating factor receptor 1 (CSF1R) signaling orchestrates TAM recruitment and polarization towards a pro-tumor M2 phenotype.
Fig.1 Summary of available therapeutic strategies to target TAMs. (Anfray, 2020)
Creative Biolabs combines deep, industry-leading expertise with an innovative Macrophage Therapeutics Development Platform to provide high-quality service in the field of macrophage development. To inhibit circulating monocyte recruitment into the tumor, our seasoned scientists have developed several strategies, including blockade of CCL2-CCR2 axis, CX3CL1/CX3CR1 axis, or CSF1/CSF1-R axis. They are happy to lend their expertise and assist our clients in employing a suitable strategy for their program and help them overcome any hurdles in inhibiting monocyte recruitment.
By assembling top-class scientific experts and integrating state-of-the-art technologies in inhibiting monocyte recruitment, Creative Biolabs has the necessary expertise and capabilities to provide overall solutions, focusing on innovative research. For more information, please feel free to contact us and further discuss with our scientists.
Copyright © 2023 Creative Biolabs. All Rights Reserved.